Cargando…
Protein Kinase RNA-activated Controls Mitotic Progression and Determines Paclitaxel Chemosensitivity through B-cell lymphoma 2 in Ovarian Cancer
Anti-tubulin agents, such as paclitaxel, have been used extensively for treatment of several types of cancer, including ovarian, lung, breast, and pancreatic cancers. Despite their wide use in cancer treatment, however, patient response is highly variable and drug resistance remains a major clinical...
Autores principales: | Yin, Ling, Zeng, Yongji, Zeng, Renya, Chen, Yuanhong, Wang, Tian-Li, Rodabaugh, Kerry J., Yu, Fang, Natarajan, Amarnath, Karpf, Adam R., Dong, Jixin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8688329/ https://www.ncbi.nlm.nih.gov/pubmed/34799660 http://dx.doi.org/10.1038/s41388-021-02117-5 |
Ejemplares similares
-
Cyclin-dependent kinase 1-mediated phosphorylation of SET at serine 7 is essential for its oncogenic activity
por: Yin, Ling, et al.
Publicado: (2019) -
The Hippo Signaling Pathway in Drug Resistance in Cancer
por: Zeng, Renya, et al.
Publicado: (2021) -
Rationale for combination of paclitaxel and CDK4/6 inhibitor in ovarian cancer therapy — non-mitotic mechanisms of paclitaxel
por: Smith, Elizabeth R., et al.
Publicado: (2022) -
The effect of propofol on chemosensitivity of paclitaxel in cervical cancer cells
por: Jin, Yanshan, et al.
Publicado: (2023) -
Apatinib enhances chemosensitivity of gastric cancer to paclitaxel and 5-fluorouracil
por: Xu, Zhiyuan, et al.
Publicado: (2019)